Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment.
Gianluca SottilottaCarmelo ManganoRosa BasileCarmela FalconeFrancesca LuiseDemetrio MegalizziGiovanna Maria NicolòVincenzo OrianaAngela PiromalliPublished in: SAGE open medical case reports (2021)
Patients with COVID-19 are at high risk of thromboembolic events; for this reason, the use of heparin is largely recommended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hematoma is a very rarely described hemorrhagic complication in patients with COVID-19. We report here two cases of iliopsoas hematoma in male patients with COVID-19 and being treated with heparin.